Bristol-Myers Squibb: Areas of Interest
 
Areas of Interest

Bristol-Myers Squibb welcomes opportunities that enhance or support our pipeline of products to address unmet medical needs in serious disease areas. In particular, we are looking for the following:


Immuno-Oncology

  • Focus on approaches that are direct acting on the immune system
    •   ─ Novel immune checkpoint inhibitors and co-stimulatory agents
  • Tumor intrinsic targets with demonstrated impact on anti-tumor immunity
  • Tumor microenvironment


Oncology

  • Agents displaying synergy with immune checkpoint inhibitors
  • Established non-immunosuppressive mechanisms of action
  • New approaches to validated cancer pathways
  • Emerging areas of cancer biology
  • Antibody drug conjugates - novel targets and late preclinical / clinical-stage programs in areas of unmet medical need
  • Out of Scope: Supportive care – BMS focuses on therapeutics


Immunoscience

  • Assets with transformative potential in IBD, Inflammatory Arthritis, SLE/lupus nephritis and other autoimmune diseases with high unmet needs
  • Out of Scope: Allergy and Asthma


Cardiovascular

  • Heart failure: acute, post-acute, HFrEF, HFpEF, cardiomyopathy
  • Highly validated targets addressing CV risk with clear specialty medicine development paths
  • Out of Scope: LDL lowering, HDL raising, Anticoagulant, Hypertension


Genetically Defined Diseases (GDD)

  • Focus on monogenic diseases
  • Clinical-stage opportunities in rare/orphan diseases targeting at or near mutant protein
  • Special interest in clinical and preclinical opportunities targeting Duchenne Muscular Dystrophy, Synuclein, Nav1.7, and Familial Cardiomyopathy (fCM – hypertrophic or dilated)

Fibrosis

  • Mechanisms that specifically block myofibroblast activation/differentiation and profibrotic macrophage activation
  • Targeted approaches to inhibition of TGF-b and other developmental pathways
  • Approaches and mechanisms that target matrix re-modeling, epithelial cell protection and repair
  • New anti-fibrotic mechanisms with data supporting target validation and some safety understanding
  • Non-invasive diagnostics and biomarkers
  • Priority fibrotic diseases include: NASH, Idiopathic Pulmonary Fibrosis, Systemic Sclerosis, IgA Nephropathy
  • Out of Scope: Eye fibrosis, wound healing, keloids, uterine (endometriosis)




Technology Interest

Chemistry

  • Novel chemistries
  • Access to new chemical matter, including macrocycle and fragment libraries
  • Novel antibody drug conjugate “payload” or linker technology


Pharmaceutical Candidate Optimization

  • Toxicogenomics: Expression levels in cells, organs, organisms indicating potential toxicity
  • ADME modeling / predicting
    •   ─ Microfluidic systems
    •   ─ Cellular models
    •   ─ Real / Artificial organs


    Clinical Biomarkers

  • Biomarkers validated in clinical samples
  • Markers with potential for use as predictive of drug (class) efficacy or safety
  • Early assays available for finding marker
  • Pharmacodiagnostics

    • Prefer platforms familiar to FDA and other Regulatory bodies
    • Capabilities for full development of biomarkers into tests
    • Commercialization capabilities, or willingness to partner with a third party
    • Regulatory experience (US and Ex-US) very helpful


      Lead Discovery and Optimization

    • High throughput Mass spec and other label free platforms
    • Intracellular biosensors for signaling nodes
    • Novel cell based assays (biomarkers and signaling pathway)
    • Complex cellular technology, 3D culture, co-culture.
    • Novel bioassay detection system

      Genomics / Biology Platforms /Bioinformatics

    • Gene editing technology (e.g. CRISPR)
    • Novel bioinformatics tools
    • Novel In vitro and in vivo models (e.g. Induced pluripotent stem cells, genetically modified animals)
    • Platforms focused in microbiome

    Biologics Manufacturing Technologies

    • Enabling technologies to edit and improve cell line productivity.
    • Process robotics that are robust and for development but not for discovery like the TapAmbr 250 system
    • Cutting edge analytical technologies for proteins
    • Bioassay technology


      Molecular Discovery Technologies and Biologics Discovery

    • in silico, in vitro, and in vivo methods for prediction of potential immunogenicity of protein therapeutics
    • in vitro selection platforms for biologic, peptide, and small molecule discovery
    • platforms enabling high throughput expression of proteins
    • emerging structure determination platforms (e.g., small angle x-ray scattering (SAXS), Cryoelectron Microscopy (CryoEM))


      Drug Delivery / Formulation

    • Subcutaneous depot controlled release technology
    • Delivery Technologies for High Concentration Injectables
    • Oral delivery of macrocyclic peptides
    • Blood to Brain Delivery systems
    • Pulmonary Delivery Systems
    • Protein Stabilization technologies


     
     
     
     


    You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.
    You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.